STOK
Stoke Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | -1 | 41.15M | $1.35B | +7 | −7 |
| Q1 2026 | 83 | +2 | 38.21M | $1.24B | +9 | −7 |
| Q4 2025 | 80 | -1 | 35.34M | $1.12B | +1 | −2 |
| Q3 2025 | 16 | +1 | 26.41M | $620.57M | +1 | n/a |
| Q2 2025 | 12 | 0 | 21.43M | $243.28M | +1 | −1 |
| Q1 2025 | 9 | -3 | 5.10M | $33.93M | n/a | −3 |
| Q4 2024 | 12 | +1 | 4.31M | $47.51M | +2 | −1 |
| Q3 2024 | 10 | +2 | 3.11M | $38.25M | +3 | −1 |
| Q2 2024 | 8 | n/a | 2.69M | $36.29M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 1.16M | n/a | $15.69M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 794.17K | n/a | $10.73M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Millennium Management ✦ | 289.07K | n/a | $3.91M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 143.64K | n/a | $1.94M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | D. E. Shaw & Co. ✦ | 137.01K | n/a | $1.85M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 114.91K | n/a | $1.55M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 35.05K | n/a | $474,000 | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 11.20K | n/a | $151,312 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 196 holders, 69.25M shares, $2.18B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 627 sh · $16,509
Officer · 2.72K sh · $86,932
Officer · 145 sh · $4,708
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology